bloodresearch.or.kr Blood Res 2018;53:71-94.

Letters to the Editor 87

Fig. 1. Brain biopsy showing characteristic findings. (A) ×100 magnification; (B) ×400 magnification. Small foci of necrosis and frequent mitosis noted. (C-I) ×400 magnification. IHC stains on tumor cells were positive for CD20 (C), BCL2 (G), BCL6 (F), and MYC (I). The Ki-67 index was ＞95% (H). Tumor cells were negative for CD3 (D) and CD10 (E).

leukemia/lymphoma with lymphopenia in a Korean. J Korean

Med Sci 2000;15:233-9.

14. Ryu JH, Park JS, Hong SI, Son SJ, Suh CI. A case adult T-cell leuke-

mia/lymphoma. Korean J Dermatol 2002;40:295-9.

15. Jung JY, Lee JH, Lee KH. A case of adult T-cell leukemia/

lymphoma. Korean J Dermatol 2007;45:58-62.

Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6: a case report

TO THE EDITOR: Primary central nervous system lympho-ma (PCNSL) is an aggressive form of extra nodal, large B-cell non-Hodgkin lymphoma, and it is usually classified

as diffuse large B cell lymphoma (DLBCL) subtype. It is confined to the brain, leptomeninges, eye, or spinal cord without evidence of systemic disease [1, 2]. Recent genetic studies have identified a prognostic role for MYC, BCL-2, and/or BCL6 translocations in systemic DLBCL [3]. B-cell lymphoma with concurrent MYC translocation and an addi-tional BCL2 or BCL6 translocation is referred to as double hit lymphoma (DHL), and the DLBCL that harbors all three translocations (MYC/BCL2/BCL6) is called triple hit lym-phoma (THL). DHL and THL are relatively common entities among systemic lymphomas and signify a worse prognosis [3]. We report the unique case of PCNSL with MYC/BCL6 rearrangement, which was successfully treated with a MATRix regimen.

CaseA 66-year-old Caucasian man presented with complaints

of vertigo, diplopia, and ataxia in August 2016. Physical

Blood Res 2018;53:71-94. bloodresearch.or.kr

88 Letters to the Editor

Fig. 2. (A) BCL6 centromere (green arrow) and telomere (red arrow). (B) MYC centromere (green arrow) and telomere (red arrow). (C) IGH locustwo signals (green arrow) and BCL2 locus only one signal present (red arrow).

exam was notable for horizontal and vertical nystagmus, mild left dysmetria, and wide-based staggering gait. There was no palpable lymphadenopathy or organomegaly. The complete blood count, renal function, and liver function tests were within normal limits. He subsequently underwent a contrast enhanced computed tomography (CT) and mag-netic resonance imaging (MRI) of the brain that was remark-able for a 1.7×1.3 cm cerebellar mass abutting the roof of the 4th ventricle without any evidence of obstructive hydrocephalus. A slit-lamp eye exam showed no evidence of involvement in the eyes. A scrotal ultrasound examination did not show any evidence of any mass lesions in either testis. He had a contrast enhanced whole body CT scan that showed no evidence of primary malignancy in the chest, abdomen, or pelvis. The patient subsequently had a suboccipital craniotomy and resection of the cerebellar mass.

Hematoxylin and eosin staining (H & E) of the excisional brain tumor sample showed sheets of large lymphoid cells with open chromatin and irregular nuclei along with prom-inent nucleoli and a small amount of cytoplasm. The im-munohistochemical (IHC) staining on the neoplastic cells demonstrated atypical lymphoid cells that strongly and dif-fusely expressed CD45, CD20 CD 79a, MUM1, and BCL2, were weakly positive for BCL6, and had a Ki-67 index of ＞95%, suggesting a rapidly proliferating lymphoma with an activated B-cell immunophenotype. Small foci of necrosis and frequent mitosis were present (Fig. 1A, B). The tumor cells did not express CD3, CD10, CD30, CD43, CD 138, EMA, and ALK-1. MYC stain showed homogeneous nuclear expression in ＞90% of cells. (Fig. 1C-I). Epstein-Barr virus (EBV) in situ hybridization was negative. Flow cytometry of the brain tumor cells revealed a medium- to large-sized lymphoid population of kappa light chain restricted B-cells expressing CD19 and CD20, and negative for CD5 and CD10.

Interphase fluorescence in situ hybridization (FISH) stud-ies were performed on paraffin-embedded tissue sections using dual color break apart probes for MYC and BCL6, and dual color, dual fusion IGH/BCL2 probes. A total of 50 interphase nuclei were scored for the presence of these rearrangements using an automated image analysis platform. Signal patterns consistent with rearrangements of the 3q27 (BCL6) and 8q24 (MYC) loci were identified in 64% and 84% of examined nuclei, respectively. Although there was no evidence of the t(14;18)(q32;q21) translocation, a signal pattern was observed indicating a deletion of the 18q21 (BCL2) locus in 28% of nuclei examined (Fig. 2). This finding was consistent with a complete loss of chromosome 18 (monosomy 18) or a specific deletion of the 18q21 (BCL2) locus. Subsequent to these results, the tumor was formally diagnosed as high-grade B-cell lymphoma, activated B-cell (ABC) subtype, with MYC and BCL6 gene rearrangements (double-hit primary CNS lymphoma), with the International Extranodal Lymphoma Study Group (IELSG) prognostic score of 1 (for the location of the tumor). Cytological and flow cytometry analysis on cerebrospinal fluid (CSF) showed small B-lymphocytes accounting for less than 0.1% of total events.

The patient began treatment with the MATRix regimen (intravenous high-dose methotrexate, cytarabine, thiotepa, and rituximab) [4]. The patient has received 3 cycles of the MATRix regimen and the atest MRI showed complete remission of the lymphoma. We have had a follow-up of 8 months since the patient completed the MATRix regimen and he continues to be in remission.

DiscussionDouble-hit (DHL) and triple-hit lymphomas are being

classified as “high grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6” within

bloodresearch.or.kr Blood Res 2018;53:71-94.

Letters to the Editor 89

the 2016 revision of the lymphoma classification by the World Health Organization (WHO) [5]. In addition to gene rearrangements, PCNSL with increased expression of MYC and BCL2 by IHC are associated with poor prognosis as well, and these are commonly known as “Double expresser (DE)” lymphomas [6]. Increased expressions of MYC alone [7, 8] or BCL6 alone [9] are independent markers of poor prognosis in PCNSL. A true double-hit PCNSL has been described only once in the past by Sakurai et al. [10]. In this particular case, the patient had CCND1/MYC trans-location on FISH testing and the disease had an aggressive course. To the best of our knowledge, the case presented here is the second case of DHL of primary CNS origin and the first one describing dual translocations of MYC and BCL6.

Management of PCNSL is cumbersome and still needs to be standardized as there are very few prospective studies done in this regard to guide the management. Although this patient had DHL, his IELSG prognostic score was sur-prisingly low at 1, indicating the limitations of this prog-nostic score, which does not include cytogenetic or molec-ular risk factors. The patient received the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) and after 3 rounds, he achieved complete remission with complete resolution of the CNS mass. We omitted thiotepa from the second round because of prolonged cytopenias. A recent phase 2 trial done by Ferreri et al. [4] showed significant improvement in the complete remission rate and overall survival in PCNSL patients receiving the MATRix combina-tion as compared to methotrexate/cytarabine and metho-trexate/cytarabine/rituximab. Whole brain radiation and in-trathecal chemotherapy have not shown any survival benefit in such cases. High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is still under inves-tigation for its use in primary CNS lymphomas [2]. Interestingly, our patient had a deletion of BCL2 and low BCL2 expression makes the prognosis slightly favorable [11], which may be negating some of the adverse effects of the rearrangement of MYC and BCL6.

DHL among PCNSL is a rare entity; however, it might be possible that we are not testing diligently for gene re-arrangements in PCNSL. The current IELSG prognostic score can be misleading in such cases and DHL or DE lymphoma of primary CNS origin needs to be treated aggressively at the outset. Future studies, which include molecular profil-ing, are needed to standardize the treatment of PCNSL.

Appalanaidu Sasapu1, Dinesh Atwal1, Giovanni Insuasti-Beltran2, Yogesh Jethava3

1Department of Internal Medicine, Division of Hematology, 2Department of Pathology and Laboratory Medicine,

University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, 3Department of Internal Medicine, Division

of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA, USA

Correspondence to: Appalanaidu SasapuDepartment of Medicine, Division of Hematology, 4301

W. Markham Street, Little Rock, AR 72205, USAE-mail: ASasapu@uams.edu

Received on Jul. 3, 2017; Revised on Jul. 27, 2017; Accepted on Aug. 30, 2017

https://doi.org/10.5045/br.2018.53.1.87

AuthorsÊ Disclosures of Potential Conflicts of InterestNo potential conflicts of interest relevant to this article

were reported.

REFERENCES1. Nayak L, Pentsova E, Batchelor TT. Primary CNS lymphoma and

neurologic complications of hematologic malignancies. Conti-

nuum (Minneap Minn) 2015;21:355-72.

2. Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treat-

ment of primary CNS lymphoma in immunocompetent patients:

guidelines from the European Association for Neuro-Oncology.

Lancet Oncol 2015;16:322-32.

3. Rosenthal A, Younes A. High grade B-cell lymphoma with re-

arrangements of MYC and BCL2 and/or BCL6: Double hit and tri-

ple hit lymphomas and double expressing lymphoma. Blood Rev

2017;31:37-42.

4. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmuno-

therapy with methotrexate, cytarabine, thiotepa, and rituximab

(MATRix regimen) in patients with primary CNS lymphoma: re-

sults of the first randomisation of the International Extranodal

Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet

Haematol 2016;3:217-27.

5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the

World Health Organization classification of lymphoid neo-

plasms. Blood 2016;127:2375-90.

6. Kim S, Nam SJ, Kwon D, et al. MYC and BCL2 overexpression is

associated with a higher class of Memorial Sloan-Kettering

Cancer Center prognostic model and poor clinical outcome in

primary diffuse large B-cell lymphoma of the central nervous

system. BMC Cancer 2016;16:363.

7. Tapia G, Baptista MJ, Muñoz-Marmol AM, et al. MYC protein ex-

pression is associated with poor prognosis in primary diffuse large

B-cell lymphoma of the central nervous system. APMIS

2015;123:596-603.

8. Gill KZ, Iwamoto F, Allen A, et al. MYC protein expression in

primary diffuse large B-cell lymphoma of the central nervous

system. PLoS One 2014;9:e114398.

9. Kreher S, Jöhrens K, Strehlow F, et al. Prognostic impact of B-cell

lymphoma 6 in primary CNS lymphoma. Neuro Oncol 2015;

17:1016-21.

10. Sakurai H, Sugimoto KJ, Shimada A, et al. Primary CNS

CCND1/MYC-positive double-hit B-cell lymphoma: a case re-

port and review of the literature. J Clin Oncol 2015;33:e79-83.

11. Brunn A, Nagel I, Montesinos-Rongen M, et al. Frequent tri-

ple-hit expression of MYC, BCL2, and BCL6 in primary lympho-

ma of the central nervous system and absence of a favorable

MYC(low)BCL2 (low) subgroup may underlie the inferior prog-

nosis as compared to systemic diffuse large B cell lymphomas.

Acta Neuropathol 2013;126:603-5.